Nxera Pharma Co., Ltd. (4565.T,SOLTF), a research-based biopharmaceutical company, on Monday announced that it will receive a $10 million milestone payment from AbbVie Inc. (ABBV), a research-based biopharmaceutical company. The payment follows the achievement of a third R&D milestone under their multi-target discovery collaboration focused on neurological diseases.
The collaboration aims to develop novel medicines targeting G protein-coupled receptors or GPCRs associated with neurological conditions.
Under the agreement, the company is eligible to receive up to $40 million in near-term research milestones and up to $1.2 billion in potential option, development and commercial milestone payments, along with tiered royalties on global sales.
The milestone relates to the identification of validated and differentiated hit molecules against a neurology target using Nxera's NxWave platform.
The company said that the collaboration was initiated in 2022.
The achievement marks the third milestone in the collaboration, following earlier milestones reached in June 2024 and September 2025.
The company said the progress reflects continued advancement of multiple targets within the partnership and supports the development of new treatments for neurological diseases.
On Friday, Nxera Pharma Co., Ltd. closed trading 3.06% lesser at JPY 1,013 on the Tokyo Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.